LENZ Therapeutics, Inc.LENZNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-58.16%
↓ 279% below average
Average (22q)
32.43%
Historical baseline
Range
High:446.10%
Low:-58.16%
Volatility
1554.8%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -58.16% |
| Q2 2025 | 55.74% |
| Q1 2025 | -0.85% |
| Q4 2024 | -9.04% |
| Q3 2024 | -7.11% |
| Q2 2024 | -34.09% |
| Q1 2024 | -46.06% |
| Q4 2023 | 14.89% |
| Q3 2023 | 34.54% |
| Q2 2023 | 22.41% |
| Q1 2023 | 35.32% |
| Q4 2022 | -52.71% |
| Q3 2022 | -9.24% |
| Q2 2022 | -2.57% |
| Q1 2022 | 62.84% |
| Q4 2021 | 29.05% |
| Q3 2021 | -31.45% |
| Q2 2021 | 135.58% |
| Q1 2021 | -15.85% |
| Q4 2020 | 176.62% |
| Q3 2020 | 446.10% |
| Q2 2020 | 0.00% |
| Q1 2020 | 0.00% |